Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 960 participants.

Also called NCT04250116

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 960 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04250116
Other papers using this trial's data
  • Antithrombotic Therapy in Patients With Atrial Fibrillation With Prior Complex PCI: A Secondary Analysis of the Randomized ADAPT AF-DES Trial Circulation. Cardiovascular interventions, 2026-09 DOI, PubMed 42464814

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04250116. Randomized; no masking; primary purpose treatment. Start 2020-04-28 (actual); primary completion 2026-05-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
Intervention (Drug)
NOAC monotherapy
Intervention (Drug)
Dual antithrombotic therapy with NOAC and clopidogrel
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct04250116
Content hash
31e55e4a4b299171963dbe4683ee1921cbd26f03f0510e92b6132f65c83a3ba0